Stockscreener 앱 받기
76.09
4.06%
2.97
시간 외 거래:
76.09
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Can Ionis Pharmaceuticals Inc. (ISI) stock sustain revenue momentumFed Meeting & Daily Oversold Bounce Ideas - newser.com
Is Ionis Pharmaceuticals Inc. stock a defensive play in 2025Weekly Trading Summary & Weekly Return Optimization Plans - newser.com
Insider Sell: Joan Herman Sells 44,000 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Can Ionis Pharmaceuticals Inc. (ISI) stock stage a strong rebound this quarterWeekly Volume Report & Weekly Breakout Opportunity Watchlist - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionWatch List & Fast Entry Momentum Alerts - newser.com
Will Ionis Pharmaceuticals Inc. stock pay special dividendsJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com
Arrowhead’s Redemplo Approval Sets Up Standoff With Ionis’s Tryngolza - Citeline News & Insights
How Ionis Pharmaceuticals Inc. stock trades during market volatilityQuarterly Profit Report & AI Driven Price Forecasts - newser.com
Why Ionis Pharmaceuticals Inc. stock attracts high net worth investorsWeekly Profit Analysis & Real-Time Chart Pattern Alerts - newser.com
Arrowhead Pharmaceuticals Steps Into The Rare Disease Market - Finimize
Price momentum metrics for Ionis Pharmaceuticals Inc. explained2025 Market Outlook & Intraday High Probability Setup Alerts - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock attractive post correctionPortfolio Gains Report & Consistent Profit Trade Alerts - newser.com
How Ionis Pharmaceuticals Inc. (ISI) stock compares with tech leaders2025 Momentum Check & Stock Portfolio Risk Management - newser.com
With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis - MedCity News
US FDA approves Arrowhead's genetic disorder drug - Reuters
Arrowhead’s plozasiran cleared for FCS; Ionis patent duel awaits - BioWorld MedTech
RNAi biotech Arrowhead wins first FDA approval - BioPharma Dive
Ionis Pharmaceuticals Completes $770M Convertible Notes Offering - TipRanks
Ionis Pharmaceuticals (IONS) Price Target Increased by 10.27% to 85.25 - Nasdaq
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead (NASDAQ:ARWR) - Seeking Alpha
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE) - BioSpace
Can Ionis Pharmaceuticals Inc. stock sustain free cash flow growthTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
What Recent Clinical Trial Updates Mean for Ionis Pharmaceuticals Stock Valuation in 2025 - Yahoo Finance
Will Ionis Pharmaceuticals Inc. stock deliver better than expected guidanceTrade Signal Summary & Expert Approved Momentum Ideas - newser.com
Biogen Completes Acquisition of Alcyone Therapeutics - Benzinga
Ionis Pharmaceuticals stock rises after positive EU regulatory opinion By Investing.com - Investing.com India
Ionis Pharmaceuticals stock rises after positive EU regulatory opinion - Investing.com
Sanofi, Lilly among winners of EU drug recommendations this week - Seeking Alpha
Ionis Pharmaceuticals (IONS) Advances with European Review for D - GuruFocus
Is Ionis Pharmaceuticals Inc. stock in correction or buying zone2025 Market WrapUp & Intraday High Probability Alerts - Fundação Cultural do Pará
Ionis Pharmaceuticals Says Dawnzera Recommended for Approval in EU for Hereditary Angioedema - MarketScreener
EU committee recommends approval of Ionis’ HAE treatment By Investing.com - Investing.com Canada
DAWNZERA Receives Positive Opinion From CHMP, Recommended For Approval In EU For Hereditary Angioedema - TradingView
1.38%
1.42%
자본화:
|
볼륨(24시간):